Rates of clinical progression according to biological Alzheimer's disease stages.

ABSTRACT:

Introduction

Predicting the rate of cognitive decline and the likelihood of progression to dementia remains a critical unmet need in clinical settings.

Methods

We assessed progression to mild cognitive impairment (MCI) and all-cause dementia in 492 individuals from the TRIAD, ADNI, and HABS-HD cohorts followed for an average of 2.49 years. Amyloid-positive participants were staged according to the Alzheimer's Association biological staging framework (A+T₂-/A+T_2MTL+/A+T_2MOD+/A+T_2HIGH+).

Results

Cognitively unimpaired (CU) individuals in the A+T_2MTL+, A+T_2MOD+, and A+T_2HIGH+ biological Alzheimer's disease (AD) stages were at significantly higher risk of clinical progression compared to non-AD C

SUBMITTER: Trudel L 

PROVIDER: S-EPMC12434706 | biostudies-literature | 2025 Sep

REPOSITORIES: biostudies-literature